VCNX Stock Overview A clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Vaccinex, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Vaccinex Historical stock prices Current Share Price US$1.21 52 Week High US$13.02 52 Week Low US$0.76 Beta 1.1 1 Month Change -67.39% 3 Month Change -74.53% 1 Year Change -87.69% 3 Year Change -99.56% 5 Year Change -99.89% Change since IPO -99.95%
Recent News & Updates
Vaccinex, Inc.(OTCPK:VCNX) dropped from S&P TMI Index Dec 20
Vaccinex, Inc.(OTCPK:VCNX) dropped from NASDAQ Composite Index Dec 19 Vaccinex, Inc. announced that it has received $2.149995 million in funding from Vaccinex (Rochester), L.L.C, FCMI Parent Co.
Vaccinex, Inc. Reports New Findings for Signal-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease Conference in Madrid, Spain Nov 01
Vaccinex Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1) Oct 10
New major risk - Financial position Aug 16 See more updates
Vaccinex, Inc.(OTCPK:VCNX) dropped from S&P TMI Index Dec 20
Vaccinex, Inc.(OTCPK:VCNX) dropped from NASDAQ Composite Index Dec 19 Vaccinex, Inc. announced that it has received $2.149995 million in funding from Vaccinex (Rochester), L.L.C, FCMI Parent Co.
Vaccinex, Inc. Reports New Findings for Signal-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease Conference in Madrid, Spain Nov 01
Vaccinex Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1) Oct 10
New major risk - Financial position Aug 16
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership Aug 14
Vaccinex, Inc. Reports Positive Data for Signal-Ad Phase 1B/2 Trial of Pepinemab in Alzheimer’S Disease Jul 31
Insufficient new directors Jul 02
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease Jun 08 Vaccinex, Inc. announced that it has received $1.75 million in funding Vaccinex, Inc. announced delayed annual 10-K filing
Full year 2023 earnings released: US$43.68 loss per share (vs US$98.05 loss in FY 2022) Apr 02 Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding Mar 28
Vaccinex, Inc. has filed a Follow-on Equity Offering. Mar 27
Vaccinex Announces 1-for-14 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of The Nasdaq Capital Market Feb 15 Vaccinex, Inc. announced that it expects to receive $3.700126 million in funding Feb 07
New major risk - Market cap size Dec 01
New major risk - Financial position Nov 15
Vaccinex, Inc. Reports Clinical Benefit in Interim Analyses from Two Phase 2 Studies of Pepinemab Combination Treatment At Society for Immunotherapy of Cancer's Annual Meeting Nov 01
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases Oct 29
Vaccinex Receives Non-Compliance Notice From Nasdaq Oct 14
Vaccinex's Next Generation ActivMAb®? Technology Published in mAbs Sep 29
Vaccinex, Inc. to Present Update on PDAC/Pepinemab Study Sep 28
Vaccinex Reports Groundbreaking Findings At Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer Sep 27
Vaccinex, Inc. Provides Nasdaq Compliance Update Sep 23 Vaccinex, Inc. announced that it has received $0.65 million in funding Aug 23
New major risk - Financial position Aug 15
New minor risk - Share price stability Jun 19
Vaccinex Receives Letter from the Listing Qualifications Staff of the Nasdaq Notifying the Company No Longer Complies with the Requirement Under Nasdaq Listing Rule 5550(b)(1) May 31
Vaccinex, Inc. announced that it has received $2.959999 million in funding from FCMI Parent Co. May 16
Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology Jan 10
Insufficient new directors Nov 16
Vaccinex, Inc. and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37Th Annual Meeting of Society for Immunotherapy of Cancer Nov 11
Vaccinex Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market Regarding Minimum Bid Requirement Oct 12
First half 2022 earnings released: US$0.24 loss per share (vs US$0.47 loss in 1H 2021) Aug 16
Insufficient new directors Apr 27
Vaccinex, Inc., Annual General Meeting, May 12, 2022 Apr 06 Vaccinex, Inc. announced that it expects to receive $6.599997 million in funding Jan 28
Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1B/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (Pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer Jan 27
Vaccinex, Inc. Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis Jan 05
Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit Sep 20
Rock star Growth Puts Vaccinex (NASDAQ:VCNX) In A Position To Use Debt Aug 17
Price target decreased to US$7.00 Jul 19 Vaccinex, Inc.(NasdaqCM:VCNX) dropped from Russell Microcap Value Index
Vaccinex, Inc. Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s Disease Jun 09
Vaccinex, Inc. Announces Initiation of Phase 2 Clinical Trial with Merck’s anti-PD-1 therapy KEYTRUDA May 19
Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX). May 04
Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology Feb 23
Vaccinex, Inc. Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform Feb 20
Vaccinex, Inc. Announces Resignation of Raymond E. Watkins as Senior Vice President and Chief Operating Officer Oct 27
Vaccinex, Inc. announced that it has received $7.474986 million in funding from FCMI Parent Co., Vaccinex (Rochester), L.L.C and other investors Oct 01
Vaccinex, Inc. Announces Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab Sep 23 Vaccinex, Inc. announced that it expects to receive $2 million in funding Shareholder Returns VCNX US Biotechs US Market 7D -67.2% -5.6% -3.5% 1Y -87.7% -1.5% 22.1%
See full shareholder returns
Return vs Industry: VCNX underperformed the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: VCNX underperformed the US Market which returned 22.1% over the past year.
Price Volatility Is VCNX's price volatile compared to industry and market? VCNX volatility VCNX Average Weekly Movement 27.5% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: VCNX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VCNX's weekly volatility has increased from 19% to 28% over the past year.
About the Company Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company’s lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer’s disease and has completed phase 2 study for treatment of Huntington’s disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer.
Show more Vaccinex, Inc. Fundamentals Summary How do Vaccinex's earnings and revenue compare to its market cap? VCNX fundamental statistics Market cap US$2.70m Earnings (TTM ) -US$18.58m Revenue (TTM ) US$388.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) VCNX income statement (TTM ) Revenue US$388.00k Cost of Revenue US$16.57m Gross Profit -US$16.19m Other Expenses US$2.39m Earnings -US$18.58m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -6.94 Gross Margin -4,171.65% Net Profit Margin -4,787.89% Debt/Equity Ratio -3.3%
How did VCNX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 23:11 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Vaccinex, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Thomas Shrader BTIG Matthew Kaplan Ladenburg Thalmann & Company Leland Gershell Oppenheimer & Co. Inc.
Show 0 more analysts 
